Page 1 | Search Results | Blood | American Society of Hematology

1-18 of 18

Sort by

Sort Order Select

Journal Articles

Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306

Reed Friend, MD, James Xenakis, Jonathan S Serody, MD, Terrance Comeau, MD, Don A. Gabriel, MD PhD, Stefanie Sarantopoulos, MD PhD, James Coghill, MD, William A. Wood, MD MPH, Andrew Sharf, Julia S Whitley, BS, Kamakshi Rao, PharmD, Christine M Walko, PharmD,BCOP, Anastasia Ivanova, PhD, Thomas C. Shea, MD, Paul M Armistead, MD PhD

Blood (2015) 126 (23): 3117.

https://doi.org/10.1182/blood.V126.23.3117.3117

Published: 2015

Journal Articles

Interval Exercise Training (IET) Is Feasible and May Improve Cardiorespiratory Performance Prior to Hematopoietic Cell Transplantation

Mathew Meeneghan, MD, Anna Snavely, PhD, Abbie Smith-Ryan, PhD, Claudio L Battaglini, PhD, Bryce B Reeve, PhD, Ethan Basch, MD MSc, Antonia Bennett, PhD, Charlotte Shatten, MA, Brett Phillips, BS, Jonathan Serody, MD, PhD, Don A. Gabriel, MD PhD, Katarzyna Joanna Jamieson, MD, James Coghill, MD, Paul M. Armistead, MD PhD, Thomas C. Shea, MD, William A. Wood, MD MPH

Blood (2014) 124 (21): 2611.

https://doi.org/10.1182/blood.V124.21.2611.2611

Published: 2014

Journal Articles

Feasibility of Daily and Weekly Symptom and Health-Related Quality of Life (HRQOL) Surveillance in Patients Receiving Hematopoietic Cell Transplantation (HCT)

William A Wood, MD, MPH, Allison M Deal, MS, Bryce B Reeve, PhD, Amy P Abernethy, MD, Claudio L Battaglini, PhD, Yoon Hie Kim, BS, Julia S Whitley, BS, Charlotte Shatten, BS, Robert N Irons, PA, Amber N Essenmacher, PA, Kimberly Wehner, PA, Alicia Pinto, PA, James Coghill, MD, Paul M Armistead, MD, PhD, Stefanie Sarantopoulos, MD, PhD, Don A. Gabriel, MD, PhD, Jonathan S Serody, MD, Thomas C. Shea, MD

Blood (2012) 120 (21): 4471.

https://doi.org/10.1182/blood.V120.21.4471.4471

Published: 2012

Journal Articles

Feasibility and Prognostic Value of VO2 peak in Patients Undergoing Hematopoietic Cell Transplantation (HCT)

William A Wood, MD, MPH, Allison M Deal, MS, Claudio L Battaglini, PhD, Bryce B Reeve, PhD, Amy P Abernethy, MD, Yoon Hie Kim, BS, Julia S Whitley, BS, Charlotte Shatten, BS, Robert N Irons, PA, Amber N Essenmacher, PA, Kimberly Wehner, PA, Alicia Pinto, PA, James Coghill, MD, Paul M Armistead, MD, PhD, Stefanie Sarantopoulos, MD, PhD, Don A. Gabriel, MD, PhD, Jonathan S Serody, MD, Thomas C. Shea, MD

Blood (2012) 120 (21): 4152.

https://doi.org/10.1182/blood.V120.21.4152.4152

Published: 2012

Journal Articles

Effectiveness and Potential Strategies to Improve Outcomes Following Chemomobilization with Etoposide + G-CSF in Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma

William A Wood, MD, MPH, Julia Whitley, BS, Ravi K Goyal, Paul M Brown, PhD, Andrew Sharf, Robert N Irons, PA, Kamakshi Rao, PharmD, Amber N Essenmacher, PA, Jonathan Serody, MD, James Coghill, MD, Paul M. Armistead, MD, PhD, Stefanie Sarantopoulos, MD, PhD, Don A. Gabriel, MD, PhD, Thomas C. Shea, MD

Blood (2011) 118 (21): 2083.

https://doi.org/10.1182/blood.V118.21.2083.2083

Published: 2011

Journal Articles

Beneficial Effect of Escalated Doses of Busulfan (BU) Delivered by Targeted Pharmacokinetics and Prolonged Continuous Infusion on Relapse Free and Overall Survival in Matched Related and Unrelated Allogeneic Transplant Patients with Hematologic Malignancies

Thomas C. Shea, MD, Christine Walko, PharmD, Anastasia Ivanova, PhD, Julia Whitley, BS, Kamakshi Rao, PharmD, Don A. Gabriel, MD, PhD, Terrance Comeau, MD, FRCPC, James Coghill, MD, Paul M Armistead, MD, PhD, Stefanie Sarantopoulos, MD, PhD, William A. Wood, MD, MPH, Jonathan Serody, MD

Blood (2011) 118 (21): 1940.

https://doi.org/10.1182/blood.V118.21.1940.1940

Published: 2011

Journal Articles

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Philip L. McCarthy, MD, Kouros Owzar, PhD, Kenneth C. Anderson, Craig C. Hofmeister, MD, David Duane Hurd, MD, Hani Hassoun, MD, Sergio Giralt, MD, Edward A. Stadtmauer, MD, Paul G Richardson, MD, Daniel J. Weisdorf, MD, Ravi Vij, MBBS, MD, Jan S Moreb, MD, Natalie Scott Callander, MD, Koen Van Besien, MD, Teresa Gentile, MD, PhD, Luis Isola, MD, Richard T Maziarz, MD, Don A. Gabriel, MD, PhD, Asad Bashey, MD, PhD, Heather Landau, MD, Thomas Martin, MD, Muzaffar H. Qazilbash, MD, Denise Levitan, MD, Brian McClune, MD, Vera Hars, MS, John Postiglione, BA, Chen Jiang, PhD, Elizabeth Bennett, BS, Susan S Barry, BA, Linda Bressler, PharmD, Michael Kelly, MA, Michele Sexton, MS, Cara Rosenbaum, MD, Hari Parameswaran, MD, MS, Marcelo C Pasquini, MD, MS, Mary M. Horowitz, MD, MS, Thomas C. Shea, MD, Steven M Devine, MD, Charles Linker, MD

Blood (2010) 116 (21): 37.

https://doi.org/10.1182/blood.V116.21.37.37

Published: 2010

Journal Articles

Effect of CMX001 on Levels of DNA Virus In Patients After Allogeneic Stem Cell Transplantation.

Don A. Gabriel, MD, PhD, Julia Whitley, BS, Kamakshi Rao, PharmD, Charles van der Horst, MD, Jonathan Serody, MD, James Coghill, MD, Stefanie Sarantopoulos, MD, PhD, Paul Armistead, MD, PhD, William Wood, MD, MPH, Thomas C. Shea, MD

Blood (2010) 116 (21): 4550.

https://doi.org/10.1182/blood.V116.21.4550.4550

Published: 2010

Journal Articles

The Efficacy and Safety of VP-16 and G-CSF as a Mobilization Regimen Prior to Autologous Stem Cell Transplantation (ASCT) for Patients (Pts) with Multiple Myeloma (MM) and Lymphoma.

William A. Wood, MD, MPH, Julia Whitley, Dominic T Moore, PhD, Jonathan S Serody, MD, Don A. Gabriel, MD, PhD, James M. Coghill, MD, Robert Irons, PA-C, Thomas C. Shea, MD

Blood (2009) 114 (22): 4225.

https://doi.org/10.1182/blood.V114.22.4225.4225

Published: 2009

Journal Articles

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.

Peter M. Voorhees, MD, Cristina Gasparetto, MD, Kristy L. Richards, PhD, MD, Reynaldo Garcia, RN, OCN, John S. Strader, Madlyn Ferraro, RN, OCN, CCRC, Jennifer MacLean, RN, Diane Winans, Dominic T. Moore, PhD, Andrew Dodd, Matthew C. Foster, MD, Don A. Gabriel, MD, PhD, Thomas C. Shea, Jonathan Serody, MD, Hendrik W. van Deventer, MD, Syed Rizvi, Robert Z. Orlowski, M.D., Ph.D., David D. Hurd, MD

Blood (2009) 114 (22): 306.

https://doi.org/10.1182/blood.V114.22.306.306

Published: 2009

Journal Articles

Symptomatic Improvement Following Intravesicular Cidofovir for the Management of BK Virus Associated Cystitis.

Larry W. Buie, PharmD, Kamakshi V. Rao, PharmD, Stacy Epstein, PharmD, Thomas C. Shea, MD, Terrence Comeau, MD, Don A. Gabriel, MD PhD, Robert Irons, PA, Barbara Eron, RN, Jonathan Serody, MD PhD

Blood (2007) 110 (11): 3007.

https://doi.org/10.1182/blood.V110.11.3007.3007

Published: 2007

Journal Articles

Mitoxantrone and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplant for Multiple Myeloma.

Anne W. Beaven, MD, Terrance Comeau, MD, Andrew Sharf, RN, Dominic T. Moore, MPH, Jonathan Serody, MD, PhD, Thomas C. Shea, MD, Don A. Gabriel, MD, PhD

Blood (2006) 108 (11): 2945.

https://doi.org/10.1182/blood.V108.11.2945.2945

Published: 2006

Journal Articles

Variations in Ex-Vivo Assessments of Hemostasis.

Don A. Gabriel, MD, Brett E. Skolnick, PhD, Lisa Payne Rojkjaer, MD, Stephanie V. Seremetis, MD

Blood (2005) 106 (11): 4052.

https://doi.org/10.1182/blood.V106.11.4052.4052

Published: 2005

Journal Articles

Effect of Recombinant Activated Factor VII (rFVIIa) on Platelet and Clotting Systems in Healthy Volunteers.

Don A. Gabriel, MD, Brett E. Skolnick, PhD, Stephanie Seremetis, MD, Philip Leese, MD, David Mathews, MD

Blood (2005) 106 (11): 4053.

https://doi.org/10.1182/blood.V106.11.4053.4053

Published: 2005

Journal Articles

Ex-Vivo Assessments in the Evaluation of Dose Response to Recombinant Factor VIIa When Administered for Bleeding Following Punch Biopsies in Healthy Volunteers.

Don A. Gabriel, MD, Brett E. Skolnick, PhD, Philip Leese, MD, David Mathews, MD

Blood (2005) 106 (11): 4055.

https://doi.org/10.1182/blood.V106.11.4055.4055

Published: 2005

Journal Articles

Long Term Effects on GVHD and Survival Following the Use of G-CSF Stimulated Bone Marrow Versus G-CSF Mobilized Peripheral Blood Stem Cells in HLA Matched Sibling Transplant.

Anne W. Beaven, MD, Thomas C. Shea, MD, Don A. Gabriel, MD, PhD, Terrance Comeau, MD, Robert Irons, PA, Dominic T. Moore, MS, MPH, Li Lin, MS, Andrew Sharf, RN, Carol Krasnov, Mark E. Brecher, MD, Jonathan Serody, MD, PhD

Blood (2005) 106 (11): 5385.

https://doi.org/10.1182/blood.V106.11.5385.5385

Published: 2005

Journal Articles

Successful Re-Engraftment after Second Allogeneic Transplantation for Graft Failure in Patients with Refractory Hematologic Malignancies.

Don A. Gabriel, MD, PhD, James Coghill, MD, Thomas C. Shea, MD, Terrance Comeau, MD, Robert Irons, P-AC, Carol Krasnov

Blood (2004) 104 (11): 5120.

https://doi.org/10.1182/blood.V104.11.5120.5120

Published: 2004

Journal Articles

Pilot Study to Test the Efficacy and Safety of Recombinant Factor VIIa (rFVIIa, NovoSeven™) in the Treatment of Refractory Hemorrhagic Cystitis Following High Dose Chemotherapy.

Aneel A. Ashrani, MD, Don A. Gabriel, MD, James L. Gajewski, MD, Nigel S. Key, MD

Blood (2004) 104 (11): 1136.

https://doi.org/10.1182/blood.V104.11.1136.1136

Published: 2004

NARROW

Reduced Intensity Continuous Infusion Busulfan for Allogeneic Hematopoietic Cell Transplant Patients with Hematologic Disorders Who Are Ineligible or Inappropriate for Treatment with a More Intensive Therapeutic Regimen: LCCC 0306

Interval Exercise Training (IET) Is Feasible and May Improve Cardiorespiratory Performance Prior to Hematopoietic Cell Transplantation

Feasibility of Daily and Weekly Symptom and Health-Related Quality of Life (HRQOL) Surveillance in Patients Receiving Hematopoietic Cell Transplantation (HCT)

Feasibility and Prognostic Value of VO2 peak in Patients Undergoing Hematopoietic Cell Transplantation (HCT)

Effectiveness and Potential Strategies to Improve Outcomes Following Chemomobilization with Etoposide + G-CSF in Patients Undergoing Autologous Stem Cell Transplantation for Lymphoma

Beneficial Effect of Escalated Doses of Busulfan (BU) Delivered by Targeted Pharmacokinetics and Prolonged Continuous Infusion on Relapse Free and Overall Survival in Matched Related and Unrelated Allogeneic Transplant Patients with Hematologic Malignancies

Phase III Intergroup Study of Lenalidomide Versus Placebo Maintenance Therapy Following Single Autologous Hematopoietic Stem Cell Transplantation (AHSCT) for Multiple Myeloma: CALGB 100104

Effect of CMX001 on Levels of DNA Virus In Patients After Allogeneic Stem Cell Transplantation.

The Efficacy and Safety of VP-16 and G-CSF as a Mobilization Regimen Prior to Autologous Stem Cell Transplantation (ASCT) for Patients (Pts) with Multiple Myeloma (MM) and Lymphoma.

Vorinostat in Combination with Pegylated Liposomal Doxorubicin and Bortezomib for Patients with Relapsed/Refractory Multiple Myeloma: Results of a Phase I Study.

Symptomatic Improvement Following Intravesicular Cidofovir for the Management of BK Virus Associated Cystitis.

Mitoxantrone and Melphalan as Conditioning Regimen for Autologous Stem Cell Transplant for Multiple Myeloma.

Variations in Ex-Vivo Assessments of Hemostasis.

Effect of Recombinant Activated Factor VII (rFVIIa) on Platelet and Clotting Systems in Healthy Volunteers.

Ex-Vivo Assessments in the Evaluation of Dose Response to Recombinant Factor VIIa When Administered for Bleeding Following Punch Biopsies in Healthy Volunteers.

Long Term Effects on GVHD and Survival Following the Use of G-CSF Stimulated Bone Marrow Versus G-CSF Mobilized Peripheral Blood Stem Cells in HLA Matched Sibling Transplant.

Successful Re-Engraftment after Second Allogeneic Transplantation for Graft Failure in Patients with Refractory Hematologic Malignancies.

Pilot Study to Test the Efficacy and Safety of Recombinant Factor VIIa (rFVIIa, NovoSeven™) in the Treatment of Refractory Hemorrhagic Cystitis Following High Dose Chemotherapy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only